阿斯利康将于广州建设放射性偶联药物生产供应基地

格隆汇
Mar 19

阿斯利康宣布,与广州经济技术开发区管理委员会达成合作,将于当地建设放射性偶联药物生产供应基地,可为中国及亚太地区患者提供此类癌症疗法。该基地将生产一款基于锕-225的放射性偶联药物,用于前列腺癌治疗。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10